AN2 Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by AN2 Therapeutics, Inc. on June 7, 2023. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Menlo Park, California. The report details the certified voting results for two proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes rather than financial performance.
Material Changes and Voting Results
As of the record date (April 19, 2023), 19,426,452 shares of common stock were outstanding. At the Annual Meeting, holders of 16,610,548 shares (85.50%) were present via proxy, constituting a quorum. The following proposals were approved:
- Proposal 1: Election of Class I Directors
- Kabeer Aziz: 14,783,208 votes For; 747,428 votes Withheld.
- Gilbert Lynn Marks, M.D.: 14,781,503 votes For; 749,133 votes Withheld.
- Rob Readnour, Ph.D.: 14,607,802 votes For; 922,834 votes Withheld.
- Broker Non-Votes: 1,079,912 for all nominees.
- Proposal 2: Ratification of Independent Auditor
- PricewaterhouseCoopers LLP: 16,558,919 votes For; 51,629 votes Against; 0 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves strictly as a disclosure of the voting results.
Key Facts for Investor Verification
- Verify the re-election of the three Class I directors (Aziz, Marks, Readnour) for terms ending at the 2026 annual meeting.
- Confirm the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2023.
- Note the high level of shareholder participation (85.50% of outstanding shares) at the Annual Meeting.
- Review the definitive proxy statement on Schedule 14A (filed April 26, 2023) for detailed background on the director nominees and auditor appointment.